Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 2.36
AMAG's Cash to Debt is ranked higher than
66% of the 917 Companies
in the Global Biotechnology industry.

( Industry Median: 20.79 vs. AMAG: 2.36 )
AMAG' s 10-Year Cash to Debt Range
Min: 2.36   Max: No Debt
Current: 2.36

Equity to Asset 0.43
AMAG's Equity to Asset is ranked higher than
59% of the 766 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. AMAG: 0.43 )
AMAG' s 10-Year Equity to Asset Range
Min: 0.34   Max: 0.98
Current: 0.43

0.34
0.98
Interest Coverage No Debt
AMAG's Interest Coverage is ranked higher than
93% of the 429 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AMAG: No Debt )
AMAG' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 5
Z-Score: 0.85
M-Score: -3.43
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -10.28
AMAG's Operating margin (%) is ranked higher than
78% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -65.07 vs. AMAG: -10.28 )
AMAG' s 10-Year Operating margin (%) Range
Min: -18217.46   Max: 8.03
Current: -10.28

-18217.46
8.03
Net-margin (%) -13.99
AMAG's Net-margin (%) is ranked higher than
78% of the 825 Companies
in the Global Biotechnology industry.

( Industry Median: -70.66 vs. AMAG: -13.99 )
AMAG' s 10-Year Net-margin (%) Range
Min: -15420.63   Max: 31.64
Current: -13.99

-15420.63
31.64
ROE (%) -6.45
AMAG's ROE (%) is ranked higher than
79% of the 862 Companies
in the Global Biotechnology industry.

( Industry Median: -21.70 vs. AMAG: -6.45 )
AMAG' s 10-Year ROE (%) Range
Min: -78.73   Max: 4.71
Current: -6.45

-78.73
4.71
ROA (%) -2.77
AMAG's ROA (%) is ranked higher than
80% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: -18.92 vs. AMAG: -2.77 )
AMAG' s 10-Year ROA (%) Range
Min: -53.55   Max: 4.55
Current: -2.77

-53.55
4.55
ROC (Joel Greenblatt) (%) -432.64
AMAG's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: -215.73 vs. AMAG: -432.64 )
AMAG' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -933.51   Max: 12.84
Current: -432.64

-933.51
12.84
Revenue Growth (%) 5.50
AMAG's Revenue Growth (%) is ranked higher than
80% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. AMAG: 5.50 )
AMAG' s 10-Year Revenue Growth (%) Range
Min: -31.2   Max: 265.9
Current: 5.5

-31.2
265.9
EBITDA Growth (%) -53.50
AMAG's EBITDA Growth (%) is ranked higher than
53% of the 626 Companies
in the Global Biotechnology industry.

( Industry Median: -8.10 vs. AMAG: -53.50 )
AMAG' s 10-Year EBITDA Growth (%) Range
Min: -74.5   Max: 320.8
Current: -53.5

-74.5
320.8
EPS Growth (%) -51.70
AMAG's EPS Growth (%) is ranked higher than
56% of the 645 Companies
in the Global Biotechnology industry.

( Industry Median: -10.20 vs. AMAG: -51.70 )
AMAG' s 10-Year EPS Growth (%) Range
Min: -51.7   Max: 78.1
Current: -51.7

-51.7
78.1
» AMAG's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AMAG Guru Trades in Q3 2013

Jim Simons Sold Out
Steven Cohen Sold Out
» More
Q4 2013

AMAG Guru Trades in Q4 2013

Jim Simons 40,176 sh (New)
Paul Tudor Jones 15,600 sh (New)
Steven Cohen 11,244 sh (New)
» More
Q1 2014

AMAG Guru Trades in Q1 2014

Jim Simons 125,160 sh (+211.53%)
Paul Tudor Jones 22,400 sh (+43.59%)
Steven Cohen Sold Out
» More
Q2 2014

AMAG Guru Trades in Q2 2014

Jim Simons 129,060 sh (+3.12%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AMAG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.69
AMAG's P/B is ranked higher than
86% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 6.41 vs. AMAG: 2.69 )
AMAG' s 10-Year P/B Range
Min: 1.12   Max: 18.97
Current: 2.69

1.12
18.97
P/S 5.83
AMAG's P/S is ranked higher than
86% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 20.67 vs. AMAG: 5.83 )
AMAG' s 10-Year P/S Range
Min: 3.62   Max: 406.82
Current: 5.83

3.62
406.82
EV-to-EBIT -32.56
AMAG's EV-to-EBIT is ranked higher than
71% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. AMAG: -32.56 )
AMAG' s 10-Year EV-to-EBIT Range
Min: 0.3   Max: 17.2
Current: -32.56

0.3
17.2
Current Ratio 11.40
AMAG's Current Ratio is ranked higher than
90% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 4.31 vs. AMAG: 11.40 )
AMAG' s 10-Year Current Ratio Range
Min: 3.27   Max: 54.4
Current: 11.4

3.27
54.4
Quick Ratio 10.81
AMAG's Quick Ratio is ranked higher than
90% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 3.96 vs. AMAG: 10.81 )
AMAG' s 10-Year Quick Ratio Range
Min: 3.02   Max: 54.33
Current: 10.81

3.02
54.33

Valuation & Return

vs
industry
vs
history
Price/Net Cash 3.98
AMAG's Price/Net Cash is ranked higher than
94% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 190.00 vs. AMAG: 3.98 )
AMAG' s 10-Year Price/Net Cash Range
Min: 1   Max: 147.92
Current: 3.98

1
147.92
Price/Net Current Asset Value 3.47
AMAG's Price/Net Current Asset Value is ranked higher than
95% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 79.32 vs. AMAG: 3.47 )
AMAG' s 10-Year Price/Net Current Asset Value Range
Min: 0.97   Max: 80.68
Current: 3.47

0.97
80.68
Price/Tangible Book 2.95
AMAG's Price/Tangible Book is ranked higher than
89% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 9.62 vs. AMAG: 2.95 )
AMAG' s 10-Year Price/Tangible Book Range
Min: 0.78   Max: 11.36
Current: 2.95

0.78
11.36
Price/Median PS Value 0.24
AMAG's Price/Median PS Value is ranked higher than
98% of the 979 Companies
in the Global Biotechnology industry.

( Industry Median: 1.97 vs. AMAG: 0.24 )
AMAG' s 10-Year Price/Median PS Value Range
Min: 0.13   Max: 66.5
Current: 0.24

0.13
66.5
Earnings Yield (Greenblatt) 18.00
AMAG's Earnings Yield (Greenblatt) is ranked higher than
88% of the 469 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. AMAG: 18.00 )
AMAG' s 10-Year Earnings Yield (Greenblatt) Range
Min: 5.8   Max: 313.7
Current: 18

5.8
313.7
Forward Rate of Return (Yacktman) -60.21
AMAG's Forward Rate of Return (Yacktman) is ranked higher than
60% of the 757 Companies
in the Global Biotechnology industry.

( Industry Median: -10.00 vs. AMAG: -60.21 )
AMAG' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -29   Max: -17.2
Current: -60.21

-29
-17.2

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:AMU.Germany
AMAG Pharmaceuticals, Inc., a Delaware corporation was founded in 1981. The Company is a specialty pharmaceutical company focused on the development and commercialization of Feraheme (ferumoxytol) Injection for Intravenous, or IV, use to treat iron deficiency anemia, or IDA. Its main source of revenue is from the sale of Feraheme, which was approved for marketing in the U.S. in June 2009 by the U.S. Food and Drug Administration, or the FDA, for use as an IV iron replacement therapy for the treatment of IDA in adult patients with chronic kidney disease, or CKD. The Company sells Feraheme to authorized wholesalers and specialty distributors, who in turn, sell Feraheme to healthcare providers who administer Feraheme primarily within hospitals, hematology and oncology centers, and nephrology clinics.The Company's core technology is based on coated superparamagnetic iron oxide particles and their characteristic properties. The development, manufacture and commercialization of pharmaceutical products are subject to extensive regulation by numerous governmental authorities in the U.S. and abroad. In the U.S., the Federal Food, Drug, and Cosmetic Act, or the FDC Act, and other federal and state statutes and regulations govern, among other things, the research and development, manufacturing, quality control (testing), labeling, record-keeping, approval, storage, distribution, and advertising and promotion of pharmaceutical products.
» More Articles for AMAG

Headlines

Articles On GuruFocus.com
AMAG Pharmaceuticals Inc. (AMAG) EVP, CFO David Arkowitz sells 2,705 Shares Feb 28 2011 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) May 06 2010 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 230,011 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. (AMAG) CFO and Chief Business Officer David Arkowitz sells 4,459 Shares Nov 12 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 05 2009 
AMAG Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 05 2009 
AMAG Pharmaceuticals Inc. (AMAG) President and CEO Brian Jg Pereira sells 5,000 Shares Aug 05 2009 

More From Other Websites
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 12 2014
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial... Sep 08 2014
AMAG Pharmaceuticals Announces Appointment of John A. Fallon, M.D. to Board of Directors Sep 08 2014
AMAG Pharmaceuticals (AMAG) is Overbought: Is A Drop Coming? Sep 05 2014
AMAG Pharmaceuticals, Inc. to Present at Upcoming Investor Conferences Aug 29 2014
Coverage initiated on AMAG Pharma by FBR Capital Aug 14 2014
AMAG PHARMACEUTICALS INC. Financials Aug 13 2014
AMAG Pharmaceuticals Appoints Robert Blood as Vice President of Legal Affairs and Chief Compliance... Aug 12 2014
AMAG PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report Aug 05 2014
AMAG Pharmaceuticals, Inc. to Participate in Jefferies Boston Healthcare Summit Aug 01 2014
AMAG Pharmaceuticals Q2 Loss Narrows as Feraheme Sales Rise Jul 30 2014
AMAG Pharmaceuticals Inc Earnings Call scheduled for 8:00 am ET today Jul 29 2014
Q2 2014 AMAG Pharmaceuticals, Inc. Earnings Release - Before Market Open Jul 29 2014
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Jul 29 2014
AMAG Pharmaceuticals Announces Second Quarter and Six Month 2014 Financial Results and Updates... Jul 29 2014
Why AMAG Pharmaceuticals (AMAG) Could Be Positioned for a Slump Jul 28 2014
AMAG Pharmaceuticals, Inc. to Host Conference Call on July 29, 2014 at 8:00 a.m. ET to Discuss... Jul 25 2014
Zacks Rank #5 Additions for Monday Jul 21 2014
AMAG PHARMACEUTICALS INC. Files SEC form 8-K, Other Events Jul 11 2014
AMAG Pharma (AMAG) is in Overbought Territory: What's Next? Jul 02 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK